NASDAQ:AVTE
Delisted

Aerovate Therapeutics Stock Forecast

etoro logo Buy AVTE
*Your capital is at risk
$2.68
+0 (+0%)
At Close: Jul 25, 2025

AVTE Performance

AVTE Dividend Payout History


# Declaration Date Ex-Date Pay Date Amount Yield
1 Apr 09, 2025 Apr 29, 2025 Apr 28, 2025 $2.40 2.56%
2 Apr 25, 2025 Apr 25, 2025 Apr 25, 2025 $0 0%

FAQ

What is the symbol for Aerovate Therapeutics, Inc. Stock and on which exchange is it traded?
The symbol for Aerovate Therapeutics, Inc. is AVTE and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Aerovate Therapeutics, Inc. Stock?
Aerovate Therapeutics, Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy Aerovate Therapeutics, Inc. Stock?
Aerovate Therapeutics, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Aerovate Therapeutics, Inc. Stock.

What's the current price of Aerovate Therapeutics, Inc. Stock?
As of the end of day on the Jul 25, 2025, the price of an Aerovate Therapeutics, Inc. (AVTE) share was $2.68.

What is the 52-week high and low for Aerovate Therapeutics, Inc. Stock?
The 52-week high for Aerovate Therapeutics, Inc. Stock is $105.00 and the 52-week low is $2.63.

What is the market capitalization of Aerovate Therapeutics, Inc. Stock?
As of the Jul 25, 2025, the market capitalization of Aerovate Therapeutics, Inc. is 77.68M.
Click to get the best stock tips daily for free!
ABOUT AEROVATE THERAPEUTICS, INC.
Aerovate Therapeutics
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
4.43% Jun 01
N
NVRI
$19.53
0.87% May 20
RUN
$12.83
15.51% May 06
GLBE
$31.61
4.05% May 05
SAP
$172.39
8.56% May 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE